Brimonidine 0.33% for Rosacea-Related Facial Erythema

NCT07431476 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

45

Enrollment

OTHER_GOV

Sponsor class

Conditions

Rosacea
Rosacea Subtype 1 (Erythematotelangiectatic)

Interventions

DRUG: Brimonidine 0.33% gel
DRUG: Placebo gel

Sponsor

Istanbul Training and Research Hospital